Pneumonia After Implementation of the Pneumococcal Conjugate Vaccine Program in the Province of Quebec, Canada

Wals, Philippe De; Robin, Eric; Fortin, Élise; Thibeault, Roseline; Ouakki, Manale; Douville-Fradet, Monique

doi:10.1097/inf.0b013e31817cf76f

Cited by 96 publications

(61 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The direct effect on pneumonia has been confirmed by review of records in children less than 1 year of age in one group health setting in Washington State [14]. Long-term trends from Quebec have also confirmed a significant reduction in lobar pneumonia in infants following the introduction of PCV7 in that Canadian province [15]. A similar impact has been demonstrated in Australia in children [16].…”

Section: The Clinical Spectrum and Burden Of Pneumococcal Diseasesupporting

confidence: 52%

Contribution of vaccines to our understanding of pneumococcal disease

Klugman

2011

Phil. Trans. R. Soc. B

View full text Add to dashboard Cite

Pneumonia is the leading cause of mortality in children in developing countries and is also the leading infectious cause of death in adults. The most important cause of pneumonia is the Gram-positive bacterial pathogen, Streptococcus pneumoniae, also known as the pneumococcus. It has thus become the leading vaccine-preventable cause of death and is a successful and diverse human pathogen. The development of conjugate pneumococcal vaccines has made possible the prevention of pneumococcal disease in infants, but has also elucidated aspects of pneumococcal biology in a number of ways. Use of the vaccine as a probe has increased our understanding of the burden of pneumococcal disease in children globally. Vaccination has also elucidated the clinical spectrum of vaccine-preventable pneumococcal infections; the identification of a biological niche for multiple pneumococcal serotypes in carriage and the differential invasiveness of pneumococcal serotypes; the impact of pneumococcal transmission among children on disease burden in adults; the role of carriage as a precursor to pneumonia; the plasticity of a naturally transformable pathogen to respond to selective pressure through capsular switching and the accumulation of antibioticresistance determinants; and the role of pneumococcal infections in hospitalization and mortality associated with respiratory viral infections, including both seasonal and pandemic influenza. Finally, there has been a recent demonstration that pneumococcal pneumonia in children may be an important cause of hospitalization for those with underlying tuberculosis.

show abstract

Section: The Clinical Spectrum and Burden Of Pneumococcal Diseasesupporting

confidence: 52%

Contribution of vaccines to our understanding of pneumococcal disease

Klugman

2011

Phil. Trans. R. Soc. B

View full text Add to dashboard Cite

show abstract

“…Another study revealed a significant decline of 72% for lobar pneumonia admissions in Canadian children [12]. A population-based study in Israel demonstrated the effectiveness of PCVs was 40.7%, for the control of alveolar pneumonias [13].…”

Section: Discussionmentioning

confidence: 99%

Effect of 7 and 13-Valent Pneumococcal Conjugate Vaccines Different Number of Doses for Pneumonia Control in 2008 and 2010 Birth Cohort Children

Hortal¹,

Meny²,

Estevan³

et al. 2015

WJV

View full text Add to dashboard Cite

“…2 Similarly, the 9-valent PCV formulation prompted similar immune responses when used in 3-and 4-dose schedules, 17 and the 10-valent vaccine has been shown to provide similar protection against IPD when given using 2+1 or 3+1 schedules. 18 Subsequent studies have confirmed that 2+1 PCV7 schedules can be highly effective at a population level in preventing IPD, [19][20][21][22] pneumonia, 23,24 and OM. 25 Early data on the impact of a 2+1 schedule of PCV13 are available, 26 and the effects of 2+1 schedules have been sufficiently encouraging for the World Health Organization 12 and national governments 11,26 to support use of a 2+1 schedule for PCV13.…”

Section: Resultsmentioning

confidence: 99%

Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine

et al. 2013

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE: Although effective in preventing pneumococcal disease, 13-valent pneumococcal conjugate vaccine (PCV13) is the most expensive vaccine on the routinely recommended pediatric schedule in the United States. We examined the cost-effectiveness of switching from 4 total doses to 3 total doses by removing the third dose in the primary series in the United States. METHODS: We used a probabilistic model following a single birth cohort of 4.3 million to calculate societal cost savings and increased disease burden from removing the 6-month dose of PCV13. Based on modified estimates of 7-valent pneumococcal conjugate vaccine from randomized trials and observational studies, we assumed that vaccine effectiveness under the 2 schedules is identical for the first 6 months of life and largely similar after administration of the 12- to 15-month booster dose. RESULTS: Removing the third dose of PCV13 would annually save $500 million (in 2011$) but would also result in an estimated 2.5 additional deaths among inpatients with pneumonia or invasive pneumococcal disease. Such dose removal would also result in 261 000 estimated otitis media and 12 000 estimated pneumonia cases annually. These additional illnesses could be prevented through modest increases in coverage. Overall, societal savings per additional life-year lost would be ∼$6 million. When nonfatal outcomes are also considered, savings would range from $143 000 to $4 million per additional quality adjusted life-year lost, depending on the assumptions used for otitis media. CONCLUSIONS: Sizable societal cost savings and a moderate pneumococcal disease increase could be expected from removing the PCV13 primary series’ third dose.

show abstract

Pneumonia After Implementation of the Pneumococcal Conjugate Vaccine Program in the Province of Quebec, Canada

Abstract: Results are reassuring as to the effectiveness of the pneumococcal vaccination program in Quebec.

Cited by 96 publications

References 14 publications

Contribution of vaccines to our understanding of pneumococcal disease

Contribution of vaccines to our understanding of pneumococcal disease

Effect of 7 and 13-Valent Pneumococcal Conjugate Vaccines Different Number of Doses for Pneumonia Control in 2008 and 2010 Birth Cohort Children

Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine

Contact Info

Product

Resources

About